An observational study in Home Parenteral Nutrition, Intestinal Failure and Central Line, sponsored by Hospices Civils de Lyon. Active, not recruiting at 1 site in France. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by Hospices Civils de Lyon · Observational
Botriomycomas are frequent benign tumors in children. Their appearance on the central catheter orifice is a known event in clinical practice, but one that has been little studied. This lesion could lead to changes in pathways and an increase in the number of sepsis events, which would promote thrombosis and thus depletion of venous capital in patients who have been dependent on a central line for many years.
This study is a pilot study which will enable us to better identify the risk factors for the development of such a tumour, and to take stock of the different treatments used and their respective efficacy.
64 studies on the registry are indexed under Intestinal Failure; 17 are open to participants now.
This study's enrollment of 240 is above the median of 60 across 19 observational studies indexed under Intestinal Failure.
Browse Intestinal Failure studies →Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pediatric patients with intestinal failures requiring a long-term central line for home parenteral nutrition in France
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatric patients requiring a long-term central line for home parenteral nutrition: * home parenteral nutrition patients * diagnosed with at least on episode of botriomycoma on their central line * 0 to 18 years of age at diagnosis of botriomycoma
Pediatric patients requiring a long-term central line for home parenteral nutrition: * home parenteral nutrition patients * never diagnosed with an episode of botriomycoma on their central line * 0 to 18 years of age at diagnosis
Appearance of Botryomycoma
genetic characteristics (origin, phototype), local factors (mechanical, infectious), and general factors (history of sepsis).
Time frame: From first diagnosis through a follow-up period of 2 years.
Recurrence of Botryomycoma
analyze risk factors for recurrence and evolution under different treatments.
Time frame: From first diagnosis through a follow-up period of 2 years.
Ran from Apr 2022 to primary completion in Apr 2024, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.